http://lookfordiagnosis.com
English
Spanish
Italian
Portuguese
French
Swedish
Milestones in Hematology and Blood Diseases
In an effort to dispel blood disorders with novel therapeutic solutions, OMICS Group International, a leading Open access Publisher and the Science Conference Organizer, announces its 2nd International Conference on Hematology and Blood Disorders on ...
PR Web (press release) - Wed, 09 Jul 2014 00:02

Biogen's multiple sclerosis drug, Plegridy receives European marketing approval
The European Commission (EC) has granted marketing authorisation for Biogen Idec.'s Plegridy (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Plegridy ...
pharmabiz.com - Thu, 24 Jul 2014 23:22

Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA(TM) for ...
[4] Chromosomal abnormalities deletion 17p (del17p) and TP53 mutation are associated with aggressive, treatment-resistant disease.[5] .... Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.
MarketWatch - Fri, 25 Jul 2014 04:26



Idelalisib (Zydelig) Approved for CLL and Lymphoma
A much anticipated new oral drug that has generated great excitement within hematologic malignancies circles has been approved in the United States. The first-in-class kinase inhibitor idelalisib (Zydelig, Gilead) can now be used in the treatment of ...
Medscape - Wed, 23 Jul 2014 10:03

ASH honors Geraldine P. Schechter, MD, and Timothy Springer, Ph.D., with ...
Since 1974, Dr. Schechter has been the cornerstone of hematologic care at the Veterans Affairs Medical Center, helping to advance the diagnosis and treatment of chronic lymphoid malignancies and autoimmune hematologic disorders. In addition to her work ...
EurekAlert (press release) - Tue, 22 Jul 2014 11:11

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the ...
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978 ...
PipelineReview.com (press release) - Wed, 23 Jul 2014 08:33

Celgene Reports Second Quarter 2014 Operating and Financial Results
... patients with newly diagnosed acute myeloid leukemia at the European Hematology Association (EHA) meeting -- Data presented from a phase I trial of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2 ...
Wall Street Journal - Thu, 24 Jul 2014 04:26

Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion ...
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978 ...
Wall Street Journal - Wed, 23 Jul 2014 03:41


1  2  3  4  5  6  7  8    ->

Last update: April 2009
Statistics